title: [Activity of vancomycin, teicoplanin and linezolid in methicillin resistant coagulase-negative Staphylococci isolates from paediatric blood cultures].
abstract: BACKGROUND
  Coagulase-negative-Staphylococci (CNS) are the major cause of bacteraemia and sepsis in newborns. CNS methicillin resistance and its loss of sensitivity to glycopeptide antibiotics, make treatment significantly more difficult in positive cocci infections.
  
  
  OBJECTIVE
  To study MIC vancomycin, teicoplanin and linezolid in different species of CNS methicillin resistant isolates from blood cultures from paediatric patients.
  
  
  METHODS
  Clinically relevant CNS methicillin resistant isolates from paediatric blood cultures from different hospitalization wards were tested. The isolates were identified by biochemical tests by means in the Combo panels 31 of MicroScan (Dade Behring, Siemens). Resistance to oxacillin and susceptibility to vancomycin, teicoplanin and linezolid were tested by microdilution panels as cited above. We also tested teicoplanin and linezolid sensitivity using Etest.
  
  
  RESULTS
  50 methicillin resistant strains were isolated: 37 (74%)S. epidermidis, 7 (14%) S. hominis, 4 (8%) S. haemolyticus and 2 (4%) Staphylococcus spp. 26 strains were observed with reduced susceptibility to vancomycin MIC = 2 mg/L, (22 S. epidermidis, 2 S. haemolyticus and 2 Staphylococcus spp.) and 21 strains with loss of susceptibility to teicoplanin, MIC = 4-16 mg/L (20 S. epidermidis and 1 S. haemolyticus). No CNS linezolid resistant was found.
  
  
  CONCLUSIONS
  There is a linear correlation between increased vancomycin MIC and teicoplanin MIC. There is a statistically significant difference (p <0.001) in the MIC of teicoplanin in the vancomycin group = 2 mg/L with respect to the vancomycin group ≤ 1 mg/L. We also observed very low levels of linezolid MIC for all strains.
authors.affiliation: Servicio de Microbiología, Hospital Infanta Cristina, Complejo Hospitalario Universitario de Badajoz, Crta de Portugal s/n 06080 Badajoz, Spain. mfolivares@eresmas.com
authors.forename: Miguel
authors.initials: M
authors.lastname: Fajardo Olivares
authors.forename: Rocío
authors.initials: R
authors.lastname: Hidalgo Orozco
authors.forename: Saray
authors.initials: S
authors.lastname: Rodríguez Garrido
authors.forename: Cristina
authors.initials: C
authors.lastname: Gaona Álvarez
authors.forename: Rosa María
authors.initials: RM
authors.lastname: Sánchez Silos
authors.forename: Ramón
authors.initials: R
authors.lastname: Hernández Rastrollo
authors.forename: Emilia
authors.initials: E
authors.lastname: Martínez Tallo
authors.forename: Juan Luis
authors.initials: JL
authors.lastname: Cordero Carrasco
mesh_terms: D000081:Acetamides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002648:Child; D002675:Child, Preschool; D024881:Drug Resistance, Bacterial; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D000069349:Linezolid; D008297:Male; D008712:Methicillin / Q000494:pharmacology; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000494:pharmacology*; D016133:Polymerase Chain Reaction; D013203:Staphylococcal Infections / Q000097:blood / Q000382:microbiology*; D013210:Staphylococcus / Q000187:drug effects; D013212:Staphylococcus epidermidis / Q000187:drug effects; D041181:Staphylococcus hominis / Q000187:drug effects; D017334:Teicoplanin / Q000494:pharmacology*; D014640:Vancomycin / Q000494:pharmacology*
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D017334:Teicoplanin; D014640:Vancomycin; D000069349:Linezolid; D008712:Methicillin